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ABSTRACT
DNA methylation is the major repression mechanism for human retrotransposons, such as the Alu family.
Here, we have determined the methylation levels associated with 5238 loci belonging to 2 Alu subfamilies,
AluYa5 and AluYb8, using high-throughput targeted repeat element bisulfite sequencing (HT-TREBS). The
results indicate that »90% of loci are repressed by high methylation levels. Of the remaining loci, many of
the hypomethylated elements are found near gene promoters and show high levels of DNA methylation
variation. We have characterized this variation in the context of tumorigenesis and interindividual
differences. Comparison of a primary breast tumor and its matched normal tissue revealed early DNA
methylation changes in »1% of AluYb8 elements in response to tumorigenesis. Simultaneously, AluYa5/
Yb8 elements proximal to promoters also showed differences in methylation of up to one order of
magnitude, even between normal individuals. Overall, the current study demonstrates that early loss of
methylation occurs during tumorigenesis in a subset of young Alu elements, suggesting their potential
clinical relevance. However, approaches such as deep-bisulfite-sequencing of individual loci using HT-
TREBS are required to distinguish clinically relevant loci from the background observed for AluYa5/Yb8
elements in general with regard to high levels of interindividual variation in DNA methylation.
Abbreviations: BRCA1, Breast cancer 1, early onset; BRCA2, Breast cancer 2 early onset; CEBPG, CCAAT/enhancer
binding protein (C/EBP) gamma; DHODH, Dihydroorotate dehydrogenase (quinone); EDAR, Ectodysplasin A recep-
tor; H3K27ac, Histone H3 Lysine 27 acetylation; H3K4me1, Histone H3 Lysine 4 monomethylation; HT-TREBS, High-








Alu elements are one of the most successful primate retrotrans-
posons, with over one million copies in the human genome.1
They are short interspersed elements (SINEs), derived from the
7SL RNA gene, that have a dimeric structure linked by a middle
A-rich region.2 The 50 ends of Alu elements house the A- and
B-boxes, which are the internal hallmarks of a RNA polymerase
III (RNAP III) promoter, and their propagation is thought to
occur via transcription by RNAP III.3 The 30ends of Alu ele-
ments have an oligo-dA-rich sequence that is crucial to their
retrotransposition mechanism (target-primed reverse tran-
scription).4-7 Currently, relatively few Alu copies are capable of
retrotransposition and those elements belong largely to the
young Alu (AluY) family and its derivatives.8,9 Some of these
elements have undergone massive expansions, specifically in
humans, thereby comprising largely human-specific subfami-
lies, such as AluYa5 and AluYb8.10 These expansions have been
driven by both “master” Alu copies and secondary “source” ele-
ments.11 Further, some of Alu subfamilies are predicted to con-
tain “stealth-driver” elements, which escape negative selection
by mobilizing at only very low rates over long periods of time.12
DNA methylation is the major epigenetic mechanism that
represses all retrotransposons in the human genome, including
Alu.13 However, Alu elements may be more affected in terms of
DNA methylation than other retrotransposons due to their rel-
atively high CpG density.14 Indeed, most Alu elements tend to
be heavily methylated in somatic tissues, with some locus- and
tissue-specific differences.15-19 They also show a unique pattern
of differential methylation in the male and female germ cells,
compared to somatic cells.20 Primate oocytes and human dys-
germinoma (primary germ cell tumors usually occurring in the
ovary) show high levels of DNA methylation, similar to somatic
cells.20 By contrast, many Alu elements, especially the young
Alu (e.g., the AluYa5 subfamily), show distinct hypomethyla-
tion in sperm.16,17,21 Consequently, Alu-specific RNAs have
been observed in spermatozoa, indicating their transcriptional
activity.17
Hypomethylation of Alu elements is not just associated with
sperm, but also with several disease states.5,22,23 It is predicted
that hypomethylation may lead to Alu retrotransposition that
can disrupt gene expression; it may also allow for Alu-mediated
recombination, which is believed to contribute to about 0.3% of
all human diseases.22 BRCA1 and BRCA2 (2 breast cancer sus-
ceptibility genes) represent 2 of the best-characterized cases of
diseases caused by Alu insertions and Alu-mediated
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recombinations.24-26 In addition to breast cancer,27 recent
reports suggest extensive hypomethylation of Alu in several
other types of cancers, such as gastric carcinoma,28 multiple
myeloma,29 epithelial ovarian cancer,30 and lung adenocarci-
noma.31 Hypomethylation of Alu in all these types of cancers is
expected to be associated with tumor progression, as a recent
meta-analysis concluded that hypomethylation of multiple
repetitive elements, including Alu, has significant negative
effects on tumor prognosis.32
Based on the propensity for Alu hypomethylation in many
cancers, efforts are underway to develop them as epigenetic
cancer biomarkers.33 Thus far, these efforts have focused on
Alu elements as an entire group, instead of studying the meth-
ylation levels of individual Alu loci. This has been due mainly
to the lack of methods that could provide reliable methylation
levels of individual retrotransposon loci in a targeted fashion
and on a genome-wide scale. Hence, it has remained largely
unknown which particular Alu loci, and how many, show early
changes in DNA methylation specifically in response to
changes in cell state, such as during tumorigenesis. In this
study, we have used high-throughput targeted repeat element
bisulfite sequencing (HT-TREBS)34,35 to derive the methylation
levels regarding >5,000 elements belonging to 2 of the most
active human Alu subfamilies, AluYa5 and AluYb8, that have
been implicated in many diseases, including breast cancer.22,24
Our data show that »90% of AluYa5/Yb8 loci are highly meth-
ylated; however, the hypomethylated loci (»10%) are often
located close to gene promoters and show high degrees of varia-
tion in DNA methylation. We have characterized this variation
in the context of tumorigenesis in the breast and with regard to
interindividual differences. The results indicate that AluYa5/
Yb8 loci proximal to promoter regions may respond to tumori-
genic events, but this response occurs in the background of
very high levels of interindividual variation in DNA methyla-
tion. In fact, genome-wide, only »1% of AluYb8 elements are
expected to be early responders specifically to tumorigenesis,
suggesting the potential use of specific Alu elements as epige-
netic biomarkers for the early detection of cancer.
Results
HT-TREBS of AluYa5 and AluYb8 in human skin-derived
fibroblast
Here, we have analyzed the DNA methylation of >5,000
individual Alu elements from one of the most commonly
used human cell lines, skin-derived fibroblast cells, using
an established protocol for HT-TREBS.34,35 We enriched
for 2 human-specific subfamilies of the young Alu group,
AluYa5 and AluYb8, using a primer scheme that took
advantage of their subfamily-specific diagnostic mutations5
(Fig. 1A). We obtained a total of 3.9 million final library
sequencing reads, after filtering for read quality. Reads
were then processed and mapped to a custom database
containing unidirectional, bisulfite-converted sequence for
the individual loci (and flanking sequence) belonging to
the AluYa5 and AluYb8 subfamilies. Given the high
sequence similarity within all AluY subfamilies, we
repeated the mapping process against databases for
elements in the AluYc, Yd, Yf, and Yk groups and dis-
carded reads which also mapped to those groups. In the
end, »63% of the mapped reads belonged to the human-
specific AluYa5 and Yb8 subfamilies, yielding methylation
levels regarding »75% of all AluYa5 and Yb8 elements in
the human genome (Supplemental Data 1). On average,
for the 3102 AluYa5 and 2136 AluYb8 elements, »30
reads were used to calculate the percent methylation at
each locus, with a minimum of 10X coverage.
The results indicated that both AluYa5 and Yb8 elements
tend to be highly methylated in the human epigenome
(Fig. 1B). For these analyses, the entire data set of 5238 loci
was divided into 3 groups: Low (0–50% methylation); Medium
(50–75% methylation) and; High (75–100% methylation). For
human skin-derived fibroblast cells, high methylation levels
were observed for nearly 90% of these human-specific Alu ele-
ments (2788 in Ya5; 1867 in Yb8). By contrast, there were
only 30 loci (»0.5%) in the “Low” category and 533 loci
(»10%) in the “Medium” category. The distribution of Ya5:
Yb8 loci within each methylation category ranged from
»60:40 to »55:45.
For these elements within the fibroblast cell line, we also
assessed the level of variability in DNA methylation as calcu-
lated by the standard deviation in methylation levels for all
reads mapped to each specific locus (Fig. 1C). Variation
appeared to be inversely correlated with the methylation cat-
egories, with 84% of the elements (3903) in the “High” cate-
gory having the lowest levels of standard deviation (SD 0-
0.15) while 40% of the elements (12 out of 30) in the “Low”
category had SD values in the highest range (0.25). Loci in
the “Medium” category showed intermediate levels of varia-
tion, with 75% (413 elements) having SD values between
0.15 and 0.25.
To test whether the methylation level of the AluYa5 and
Yb8 elements correlated with any positional bias, we mapped
their distance to the nearest transcription start site (TSS)
using the genomic regions enrichment of annotations tool
(GREAT 36) (Fig. 1D). For AluYa5 and Yb8 elements meth-
ylated at high or medium levels, most were found 5–500 kb
from the nearest TSS. In contrast, those methylated at low
levels were often (though not exclusively) found within 5 kb
upstream of the TSS. Thus, most AluYa5 and AluYb8 ele-
ments are not present near gene-rich regions; however, those
with low levels of methylation may be more frequently asso-
ciated with proximity to gene promoters.
Characteristics of AluYa5 and AluYb8 elements located
near gene promoters
A search for the nearest gene with a TSS within 1 kb of the AluYa5
and Yb8 elements in our data set detected 18 genes, with equal
numbers associated with AluYa5 vs. AluYb8 elements. With
respect to their association with Alu loci methylation categories,
the 18 genes were distributed as follows: “Low”, 7 genes (»40%);
“Medium”, 4 genes (»20%) and; “High”, 7 genes (»40%). This
highlights the proximity bias of low-methylation AluYa5/Yb8 ele-
ments; over 20% of the 30 elements with low levels of methylation
were located within 1 kb of the nearest transcription start site,
whereas only 0.1% of loci in the high-methylation (7 out of 4655)
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and 0.7% of those in the medium-methylation group (4 out of 553)
were present so close to a gene (Fig. 1D, Table 1).
The data in Table 1 also suggest that most AluYa5 and Yb8
elements found proximal to gene promoters often bear active
epigenetic signatures in a tissue-specific manner. For instance,
in several tissues, nearly 60% (10/18) of these Alu elements
were found along the shores of regions bearing histone marks
indicative of enhancer regions,37-39 with especially strong
acetylation on lysine 27 of histone H3 (H3K27ac) signals, and
somewhat weaker signals for monomethylation on lysine 4 of
histone H3 (H3K4me1) for some of these elements (data not
shown). Next, consistent with the results of our study, nearly
all elements from the “Low” and “Medium” methylation groups
were also found to be hypomethylated in various other normal
and cancer cell lines.40-45 Finally, nearly all AluYa5/Yb8
elements in the high methylation category in fibroblast cells (as
Figure 1. HT-TREBS of AluYa5 and AluYb8 in human fibroblast cells. (A) Primer scheme depicting the enrichment of AluYa5 and AluYb8 sequences using HT-TREBS. Briefly,
methylated Ion Torrent “A” adaptors were ligated to sheared and size-selected genomic DNA, and the sample was bisulfite-treated. Ion “A” primers and subfamily-specific
primers (with Ion “P1” adaptor on their 50 ends) amplified fragments containing part of the Alu element (the first monomer and middle A-rich region) along with some
flanking genomic sequence. (B) Methylation profile for AluYa5 and AluYb8 elements, binned in increments of 5%, for the 5238 loci sequenced. Loci were subdivided into
3 broad groups roughly corresponding to the inflection points in the graph: Low (0–50%), Medium (50–75%) and High methylation (75-100%). (C) Characterization of
loci in terms of variation in methylation level (expressed in standard deviation, SD) for the 3 methylation groups. Dashed horizontal lines represent the thresholds used in
the analysis (SD 0.15 and 0.25). Variation in DNA methylation was generally observed to be lower for highly methylated elements compared with those in the medium
and low methylation groups. (D) Distance of AluYa5 andYb8 elements to the nearest transcription start site (TSS) based on methylation level. Alu elements with low levels
of methylation appeared more likely to be present close to gene promoters compared with those methylated at >50% levels.
Table 1. Characteristics of AluYa5/Yb8 elements located within 1-kb of the nearest transcription start site (TSS) and their associated gene. Loci were subdivided into three
broad groups: Low (0-50%), Medium (50-75%) and High methylation (75-100%). Negative sign (-) indicates that the gene is upstream of the transcription start site (TSS).
Gene Alu Subfamily Methylation Level (%) Group Distance to nearest TSS (bp) H3K27ac shore Hypo-methylated Tissue(s)
OR10Q1 Ya5 82 High -160 — Sperm
OSBPL10 Ya5 17 Low -160 Yes Various
TMSB4Y Ya5 24 Low -200 — Various
yUBE2T yYa5 8 Low 529 Yes Various
yCEBPG yYa5 83 High -578 Yes Various
HIGD1B Yb8 66 Medium -603 — —
yDHODH yYb8 21 Low 634 Yes Various
RABEPK Yb8 44 Low -660 Yes Various
UGGT2 Ya5 17 Low -698 Yes Various
HENMT1 Ya5 66 Medium 729 — Various
INTS5 Yb8 97 High -779 Yes Sperm
HTR3E Yb8 83 High -783 Yes Sperm
yMAP3K7 (TAK1) yYb8 20 Low 798 Yes Various
AASDH Yb8 66 Medium 830 Yes Various
ADAD1 Ya5 88 High -854 — Sperm
IDNK Yb8 84 High -931 — Sperm
yEDAR yYb8 61 Medium -936 — —
EIF2B1 Ya5 89 High 952 — Sperm
y Loci further characterized in this study
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well as most loci in the low and medium categories) were none-
theless hypomethylated in sperm.21
Gene-associated AluYa5/Yb8 elements show variable
DNA methylation
Most of the genes located within 1 kb of the 18 Alu elements
have previously been found to be misregulated in various differ-
ent cancers (Supplemental Fig. 1). Hypothesizing that such
changes could affect nearby Alu elements, we assessed the meth-
ylation levels of Alu elements located near 5 genes (CEBPG,
UBE2T, EDAR, DHODH, and MAP3K7/TAK1) as well as their
endogenous promoters. Two genes, CEBPG and UBE2T, were
associated with elements from the AluYa5 subfamily; the other 3
genes were associated with elements from the AluYb8 subfamily.
Using two independent approaches, combined bisulfite restric-
tion assay (COBRA46) and NGS-based bisulfite sequencing of
the amplicons, we tested the methylation level of these 5 Alu loci
in 5 samples: matched breast normal, matched breast tumor,
breast cancer, lung normal, and lung cancer.
The COBRA results showed that 4 out of the 5 loci showed
significant variation in at least one of the 3 cancer samples
(Fig. 2A-F). CEBPG-Alu was the most affected, showing signifi-
cant hypermethylation by 20% on average in the matched breast
tumor, and hypomethylation by 16% on average in the
unmatched breast cancer sample. This particular locus was also
affected especially severely in the lung cancer sample, showing
near-complete demethylation (Fig. 2A). UBE2T-Alu and
EDAR-Alu also seemed affected in the context of breast tumori-
genesis (Fig. 2B, C), with UBE2T-Alu showing almost no meth-
ylation in both the matched breast tumor as well as the
unmatched breast cancer sample, and EDAR-Alu showing 25%
less methylation only in the unmatched breast cancer. In addi-
tion to CEBPG-Alu, lung cancer samples were hypomethylated
by 10% for EDAR-Alu and by 12% for DHODH-Alu (Fig. 2C,
D). The fifth locus, MAP3K7-Alu, showed no significant differ-
ence between any of the normal and cancer samples (Fig. 2E).
Fig. 2F summarizes the COBRA-derived variation in methyla-
tion in the cancer samples relative to their normal controls.
The methylation patterns of 3 out of the 5 loci, CEBPG-Alu,
EDAR-Alu and DHODH-Alu, were further tested with next-
generation-sequencing on the bisulfite-PCR products. Overall,
the bisulfite-NGS confirmed the COBRA results, demonstrating
hypermethylation of CEBPG-Alu in the matched breast tumor
and hypomethylation in the lung cancer samples (Fig. 3), as
well as being concordant for EDAR-Alu and DHODH-Alu
(Supplemental Figs. 2–3). Detailed analysis of the sequencing
pattern also showed that the methylation of the CpG sites asso-
ciated with the A- and B-boxes of the elements showed no
unique patterns and was similar to nearby CpG sites which did
not correspond to any functional element (Fig. 3B). Addition-
ally, variation in Alu methylation was unrelated to the methyla-
tion status of the endogenous gene promoters, which were
completely unmethylated in all samples, aside from some
hypermethylation at the CEBPG promoter in lung cancer (Sup-
plemental Figs. 4–5). In sum, based on the COBRA and bisul-
fite-NGS data, we conclude that locus-specific differences in
Figure 2. Methylation variation of AluYa5 and Yb8 loci closely associated with a gene in normal and cancer samples. Alu elements are named after their associated gene.
(A-E) Methylation levels are quantified through COBRA, followed by densitometry, in 5 tissues: matched breast normal (Br-mat-N); matched breast primary tumor (Br-
mat-T); breast cancer (Br-C); normal lung (Lu-N); and lung cancer (Lu-C). Bands are labeled as either methylated (red “M”) or unmethylated (blue “U”), along with the
appropriate restriction enzyme.  P < 0.05;  P  0.01;  P  0.001;  P  0.0001. Error bars indicate standard error of mean (SEM). (F) Relative to the appropri-
ate control, CEBPG-Alu, UBE2T-Alu, EDAR-Alu and DHODH-Alu showed significant difference in methylation in at least one test sample. Heatmap summarizes the results
as hypermethylation (red), hypomethylation (green), and no significant change (gray).
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methylation exist for AluYa5 and AluYb8 elements proximal to
4 cancer-associated genes in breast and lung cancer samples.
The changes observed in the breast tumor relative to the
matched normal can be attributed to tumorigenesis, suggesting
that methylation levels of UBE2T-Alu and CEBPG-Alu are
likely to respond to changes in cell state.
Interindividual variation in AluYa5 and AluYb8 elements
Various molecular events during normal development, inde-
pendent of those related to tumorigenesis, may potentially lead
to interindividual variation in Alu DNA methylation. To assess
the background level of variation in DNA methylation at these
Alu loci, we tested the DNA methylation levels in 8 normal
breast tissues by COBRA and bisulfite-NGS for CEBPG-Alu,
DHODH-Alu, EDAR-Alu and UBE2T-Alu. Methylation levels
were high enough for accurate quantitation in only 2 of the 4
loci, with the range in normal tissue being »9–85% for
CEBPG-Alu and »9–80% for DHODH-Alu (Fig. 4A). Further,
NGS-based bisulfite sequencing supported the COBRA data by
showing various different methylation patterns between the 8
normal and 8 tumor samples (Supplemental Fig. 6A-C). Over-
all, the data suggest that AluYa5 and Yb8 loci close to gene pro-
moters are likely to show high levels of interindividual variation
in DNA methylation.
To determine whether some of the variation could be
tumor-related, we then compared the COBRA methylation
data obtained from the normal breasts to those from 40
breast tumor samples. For these analyses, we grouped all
individual methylation counts into normal vs. tumor sam-
ples. With respect to overall methylation state, the pooled
site data (BstUI and HpyCH4III) for CEBPG-Alu showed no
significant differences between normal and tumor samples
(Wilcoxon-Mann-Whitney test, Fig. 4B). However, analyzed
separately, significant hypomethylation in the tumor was
observed at the HpyCH4III site (Fig. 4C-D). We also quanti-
fied the percentage of normal and tumor samples in 5 meth-
ylation-ranges: Low (0–20%), Medium-Low (20–40%),
Medium (40–60%), Medium-High (60–80%) and High (80–
100%). Here, regardless of whether the COBRA sites for
CEBPG-Alu were analyzed separately or together, »25%
Figure 3. Methylation variation of CEBPG-Alu in normal and cancer samples. (A)
Heatmaps show the methylation patterns of the CEBPG-Alu locus (after nested
PCR) in the 5 samples described in Fig. 2. Red and blue in the heatmap indicate
methylated and unmethylated CpG sites, whereas white marks CpG sites with
unknown methylation status. CpG sites within actual Alu elements are enclosed by
black rectangles. The % methylation is shown for the entire amplicon (top) as well
as for CpG sites within vs. flanking the AluYa5 element (bottom). Significant differ-
ences (P < 0.0001) are shown with a large asterisk. Arrowheads indicate the A-box
(gray) and B-box (purple) in the Alu element [top], and CpG sites analyzed by
COBRA (BstUI, green; HpyCH4III, orange) [bottom]. (B) Methylation levels of a few
pertinent CpG sites within the locus (marked by the arrowheads) in the 5 samples.
Figure 4. Interindividual variation in DNA methylation of AluYa5 and Yb8. (A) Heatmap showing the average methylation level of CEBPG-Alu and DHODH-Alu in 8 normal
and 40 breast tumor samples as determined by the COBRA assay: dark blue, 0–20% methylation (Low); blue, 20–40% (Medium-Low); green, 40–60% (Medium); gold, 60–
80% (Medium-High); and red, 80–100% (High). (B-G) Variation in methylation levels for CEBPG-Alu in normal vs. tumor samples for CpG sites recognized by: both BstUI
and HpyCH4III (B, E); BstUI only (C, F); and, HpyCH4III only (D, G). Panels B-D represent statistical analyses of data from all samples as pooled into normal vs. tumor, with sig-
nificant hypomethylation only at the HpyCH4III site; Panels E-G depict the relative numbers of samples in each group as pooled into 5 levels of variation in methylation,
with more tumor samples methylated at Low (0–20%) levels at all tested CpG sites.
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more tumor samples were methylated in the low range com-
pared to normal (Fig. 4E-G). Altogether, this analysis indi-
cated the presence of interindividual variations at AluYa5
and AluYb8 loci located close to gene promoters, with the
methylation level at one CpG site in CEBPG-Alu being sig-
nificantly lower in the breast tumor sample set.
Aberrant DNA methylation of AluYa5 and AluYb8 in
response to tumorigenesis
Despite the large interindividual variation in DNA methylation
documented through the 8 normal samples, initial analysis of
the matched breast pair suggested that at least 2 loci, CEBPG-
Alu and UBE2T-Alu, responded specifically to tumorigenesis
(Fig. 2A-B). To determine how many AluYa5 and Yb8 elements
are likely to respond similarly genome-wide, we performed
another HT-TREBS on the same matched breast normal and
primary tumor. Reads for normal (6.3 million) and tumor (6.8
million) samples were processed as described for the fibroblast
cells, yielding methylation values regarding 104 AluYa5 and
1776 AluYb8 elements with a minimum of 10X coverage in
both the normal and tumor samples (Supplemental Data 2).
Initial analysis of the HT-TREBS results revealed a subtle
trend toward hypomethylation of AluYa5/Yb8 elements in the
breast tumor compared to normal (Fig. 5A). For instance, in
terms of their percentages of Alu elements, there was a disparity
between the tumor and normal samples within the 85–100%
methylation level, with »10% of the tumor elements being
shifted into the 65–85% methylation range. In fact, 36% of all
loci with methylation levels of <85 % were unique to the tumor
sample, while 55% were common to both the normal and the
tumor (inset in Fig. 5A). Next, to determine the pattern of
change for individual elements, the methylation level of each
AluYa5/Yb8 locus in the tumor sample was plotted against the
normal (Fig. 5B). Most loci clustered between 80–100% methyl-
ation, with a minority of loci ranging between 20–80% methyl-
ation. Loci falling on the diagonal y D x line represent Alu
elements showing no change in DNA methylation during
tumorigenesis; deviations from the line represent loci showing
differential methylation between the 2 samples. Loci were con-
sidered to be responding to tumorigenesis if they deviated by at
least 20% in in their methylation between normal and tumor
samples; at this threshold, as few as 10 reads were sufficient to
establish statistical significance. Twenty-two loci (all AluYb8)
were differentially methylated at >20% levels, with 19 loci
(»86%) showing hypomethylation in the tumor (Supplemental
Data 2). Overall, the HT-TREBS data on the matched breast
pair revealed that the primary breast tumor had at least 4X
more uniquely hypomethylated loci than its matched normal
sample. Furthermore, about 1% of AluYb8 loci are expected to
show at least 20% difference in methylation in response to
tumorigenesis.
Close examination of the 22 AluYb8 loci showed that, along
with a decrease in DNA methylation, these loci also displayed
an increase in the variability of their methylation state
(Fig. 5C). As seen in the individual heatmaps, this change is the
result of read-specific hypomethylation, either in the entire
span or in only the 50 end of the Alu element (Fig. 5D). Assum-
ing that each individual methylation read is derived from the
DNA from different cells, this pattern indicates the accumula-
tion of cells in the primary tumor which are losing DNA meth-
ylation at these loci. To test whether these early changes in
DNA methylation correlate with events in later stages of breast
cancer, we searched The Cancer Genome Atlas (TCGA) for the
Figure 5. Tumorigenesis-related variation in DNA methylation of AluYb8. HT-TREBS analysis of matched breast normal and primary tumor tissues showing tumorigenesis-
related variations in DNA methylation of AluYb8 elements. (A) Methylation profile of the normal (orange) and tumor (blue) samples, based on the percent Alu elements
belonging to methylation bins in increments of 5%. The venn-diagram (inset) shows the 4X higher number of hypomethylated loci (<85% methylation; dotted line) in
the tumor (blue) compared to the normal tissue (orange). (B) Methylation level of individual Alu loci in the matched breast tumor vs. normal, with each dot representing
one Alu locus. Most loci follow the yD x dotted line, indicating no major difference in methylation between the 2 tissues. (C) Variation in methylation (standard deviation)
vs. methylation level of the 22 differentially methylated AluYb8 loci, indicating lower methylation and higher levels of variation in the tumor tissue (blue) compared to the
normal tissue (orange). (D) Heatmaps showing methylation levels of 2 AluYb8 loci in normal and tumor tissues. (E) Summary of information with respect to the nearest
gene associated with the 22 differentially methylated AluYb8 loci (green for hypomethylation and red for hypermethylation). Negative sign (¡) indicates that the gene is
upstream of the Alu element; “N/A” indicates no gene within 1000 kb of the Alu element. Gene regulation information is from the invasive breast cancer (BRCA) and Pan-
Cancer (PANCAN) data sets from TCGA; using Student t-test (P <0.05), genes were classified as downregulated (blue) or upregulated (gold). Gray indicates no significant
change.
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gene nearest to the Alu elements and determined whether that
gene showed any misexpression in the invasive breast cancer
(BRCA) or Pan-Cancer (PANCAN47) data set from TCGA
(Fig. 5E). Of the 22 loci responding to tumorigenesis, 14 had
their nearest gene misexpressed in both the invasive breast
cancer as well as in the PANCAN set. Considering the 2
data sets combined, the AluYb8 elements appeared to be
associated with a significantly greater number of downregu-
lated genes than upregulated genes (P D 0.02, chi-square
test). This gave rise to a slight correlation between hypome-
thylated loci in breast tumor and downregulated genes in
the invasive breast cancer stage. With regard to the BRCA
data set, 8 out of 19 (42%) loci hypomethylated in the pri-
mary breast tumor were associated with a gene downregu-
lated in breast cancer, and 4 (21%) loci were associated
with an upregulated gene (Fig. 5E). Unfortunately, however,
the significance of this correlation could not be established
due to the small sample number. Overall, detailed analysis
of the 1% AluYb8 elements responding to breast tumorigen-
esis indicates that a fraction of the tumor cells may show
complete unmethylation of the Alu locus, either in part or
in its entirety. Further, such changes in DNA methylation
of Alu elements may serve as early indicators of down-
stream aberrations in gene expression, characteristic in the
later stages of breast cancer.
Discussion
Here, we have determined DNA methylation levels regarding
5238 individual Alu loci belonging to the AluYa5 and AluYb8
subfamilies. Consistent with previous results, we find that
»90% of these elements are highly (>75%) methylated
(Fig. 1B), presumably as a means of repressing expression of
retrotransposons in the human genome. Nevertheless, »10% of
the elements are hypomethylated and tend to be located in
regions of active chromatin (Fig. 1D, Table 1), potentially
allowing them to escape this repression mechanism. Interest-
ingly, these hypomethylated loci exhibit high variation in their
methylation status from cell to cell in a tissue sample (Fig. 1C).
Loci near gene promoters also tend to show high levels of inter-
individual variation in DNA methylation (Fig. 4A, Supplemen-
tal Fig. 6).
The existence of Alu elements with variable levels of retro-
transposition activity, secondary and “stealth” drivers, have
been proposed in previous studies;11,12 yet, the molecular mech-
anisms underlying these models remain unclear. Given that
DNA methylation is one of the major epigenetic mechanisms
repressing Alu retrotransposition, we speculate that interindi-
vidual variations in DNA methylation, as reported here for
AluYa5 and AluYb8 elements near gene promoters (Fig. 4, Sup-
plemental Fig. 6), might play an important role. After all, for
“stealth” drivers and secondary elements to be successful, they
must be repressed in most individuals in order to maintain low
retrotranspositional activity within the overall population. Dif-
ferential repression of Alu elements between individuals is
likely to be at the epigenetic level because the epigenome is
highly plastic and easily influenced by various environmental
factors. Further, because only a few individuals in a population
are expected to have very low levels of DNA methylation at an
Alu locus, very few copies should be active at the population
level, with others being methylated (and perhaps active) at vari-
ous different levels. Thus, differential methylation of the
human-specific Alu elements, as found in this study, may
decouple them from selection pressures and allow their contin-
ued propagation according to the Stealth Model.12
With respect to disease, hypomethylation at Alu elements
has been associated with various cancer types, and it may have
a bearing on tumor prognosis;32 however, there is a low pene-
trance of cancer incidences which can be directly attributed to
Alu activity. The high interindividual variation in methylation
of Alu elements proximal to promoter regions may be a con-
tributing factor toward the low penetrance phenotype. Only a
small fraction of the population is expected to harbor severely
hypomethylated Alu loci, potentially increasing their chances
of developing cancer. The underlying mechanism could be
either Alu retrotransposition or its activity in cis. As discussed
below, cis activity is especially interesting with regard to Alu
elements proximal to cancer-associated genes, such as CEBPG-
Alu (Fig. 4, Supplemental Fig. 6). In addition to the evolution-
ary perspective, further investigations regarding interindividual
variation in Alu methylation may prove fruitful in relation to
elucidating disease susceptibility factors.
A long standing question regarding the role of Alu retro-
transposons in cancer has been whether they can be drivers of
tumorigenesis or if they are simply “passengers.” Answering
this question involves understanding how many Alu elements
are likely to affect nearby gene promoters in cis. Here, focusing
on only 2 subfamilies of human-specific Alu elements, we
report characteristics for 18 AluYa5 and Yb8 elements located
within 1 kb of a gene promoter (Table 1). Many of these loci
are both hypomethylated and are located near enhancer regions
in various tissues, with some bearing active histone marks
themselves. Moreover, nearly all of these loci are associated
with genes that are frequently misregulated in cancer (Supple-
mental Fig. 1). Two loci, UBE2T-Alu (chr1:202310424-
202310734) and CEBPG-Alu (chr19:33863506-33863809) are
particularly noteworthy for the following reasons:
1.Early changes in DNA methylation during tumorigenesis
were displayed by the AluYa5 elements associated with both
of these genes, as seen in significant changes in a primary
breast tumor relative to the matched normal. CEBPG-Alu
was hypermethylated; by contrast, UBE2T-Alu was hypome-
thylated (Figs. 2–3).
2.Both elements are closely associated with tumor-suppressor/
oncogenes and are located within the active promoter
regions of their respective genes. In addition, CEBPG-Alu
shows some enhancer-related histone marks in some cell
lines (e.g., HMEC, normal human mammary epithelial
cells),38,39 suggesting potential functional exaptation of the
locus.
3.Both elements have potential function as cis elements, being
associated with genes that are directly involved in tumori-
genesis. UBE2T is frequently overexpressed in breast cancer
and is thought to aid in breast carcinogenesis by downregu-
lating BRCA1.48 CEBPG, by contrast, is mainly a lung cancer
gene, with interindividual differences in expression level of
CEBPG being associated with the risk of lung cancer.49,50 In
this study, CEBPG-Alu showed interindividual differences
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in methylation in the breast tissue (Fig. 4); assuming similar
interindividual variation exists at the Alu locus in the lung,
it may correlate with interindividual variation in CEBPG
expression.
In summary, based on their methylation profiles in normal
and cancer samples, we have identified several Alu elements for
further research into their potential roles as drivers of
tumorigenesis.
Regardless of their role as “drivers” or “passengers,” Alu ele-
ments have the potential to serve as epigenetic cancer bio-
markers. We performed HT-TREBS on a primary breast tumor
and its matched normal sample, and found 22 elements (»1%)
with signatures of being early responders to breast tumorigene-
sis. These elements all belong to the AluYb8 subfamily and they
are all located far from promoter regions (Fig. 5). Alu hypome-
thylation has been considered to be a later event in breast carci-
nogenesis, given that significant changes in overall Alu
methylation were not seen until the later more invasive stages.27
Thus, the percentage of ‘early responders’ may vary among
tumor types; for example, we expect it to be much higher in lung
cancer where Alu hypomethylation is considered to be an early
event.31 Here, even in an early stage of breast tumor and using
very stringent criteria, deep-sequencing of 1800 individual
AluYa5/Yb8 loci revealed that the primary tumor had 4 times
more uniquely hypomethylated loci (with  85% methylation)
than the normal tissue (Fig. 5A), and that 19 of these loci showed
significant hypomethylation in a read-specific manner only in
the tumor (Fig. 5D). The greater number of reads showing com-
plete unmethylation at the 50 end of the Alu loci (which house
the regulatory elements for Alu propagation) may indicate an
accumulation of cells within the tumor sample which are
completely losing DNAmethylation at this locus.
These results demonstrate that HT-TREBS is capable of
detecting when very few cells within a potentially cancerous tis-
sue show loss of methylation at a locus. In fact, as few as 10
reads were deemed sufficient to establish statistical significance
when the difference in methylation was at least 20%. Further,
according to TCGA, many of the genes found within 1000 kb
of these 22 AluYb8 elements showed a significant change in
their expression level in invasive breast cancer as well as in the
PANCAN data set (Fig. 5E).47 This suggests that Alu elements
located far from genes, which show an early change in DNA
methylation during tumorigenesis, may be good biomarkers for
the early detection and risk-assessment of cancer. However,
given their distance from the associated genes, it seems likely
that these Alu elements are merely neutral bystanders (a.k.a.,
“passengers”) in the genome, and that their methylation levels
are only indicative of a certain cell state. Taken together, these
factors render HT-TREBS a potentially useful technique in
detecting epigenetic biomarkers for the early detection of can-
cer through the deep-bisulfite-sequencing of individual loci of
the targeted retrotransposon.
Materials and methods
HT-TREBS analysis of AluYa5 and AluYb8
The established protocol for HT-TREBS34,35 was used for this
study, with some modifications. Purified DNA was sonicated to
a mode of »700-bp fragments, end-repaired and ligated to cus-
tom-designed Ion Torrent “A” adaptors with methylated cyto-
sines (Integrated DNA Technologies). Excess adaptors and
DNA fragments <300-bp were then removed using Agencourt
AMPure XP beads (Beckman Coulter). The final product was
subjected to a bisulfite conversion reaction using EZ DNA
Methylation
TM
kit (Zymo Research) according to manufac-
turer’s protocol. The bisulfite-converted DNA was then ampli-
fied with a forward primer complementary to the Ion
Torrent “A” adaptor and reverse primers specifically designed
to select for AluYa5 (50- CCACTACGCCTCCGCTTTCCT
CTCTATGGGCAGTCGGTGAT^CAAATAACTAAAACTA-
CAAACRCCCRCCACT -30) and AluYb8 (50- CAC-
TACGCCTCCGCTTTCCTCTCTATGGGCAGTCGGTGAT^
CTCTATCRCCCAAACCRAACTACTA -30) using their diag-
nostic mutations.5 The sequence before the caret (^) belongs to
the Ion Torrent “P1” adaptor which was included as a 50-exten-
sion on the reverse primers; ‘R’ stands for either ‘A’ or ‘G’
(IUPAC DNA nomenclature). The PCR products from the sep-
arate “AluYa5” and “AluYb8” reactions were then size-selected
to a range of 450–500 bp in length using the E-gel Precast Aga-
rose Electrophoresis System (Life Technologies), purified by
Select-A-Size DNA columns (Zymo Research), quantified on
the Bioanalyzer DNA-HS chip (Agilent Technologies) and
combined in equimolar concentrations. The combined library
was templated on the IonTM OneTouch 2 (using the Ion PGM
Hi-QTM OT2 Kit) and then sequenced on the Ion PGM (using
the Ion PGM HiQ Sequencing Kit and a 318-v2 chip). Sequenc-
ing reads were first filtered for quality and size by the Ion Tor-
rent Suite software (v-4.4.3). All remaining reads >100-bp in
length were then used for mapping using Bowtie2.51 Reference
genomes were custom-prepared for the mapping, which con-
sisted of »20,000 Alu sequences from 6 AluY subfamilies (a, b,
c, d, f, and k) plus 700-bp flanking regions, from Human
Genome Build hg19, in which all non-CpG cytosines were con-
verted to thymines and all CpG cytosines to ‘Y’ (IUPAC ambig-
uous base for C/T). The mapped reads were then processed
using various Perl scripts to yield only those sequences which
contained the Alu and at least 10-bp of flanking genomic
sequence. The filtered reads were then processed through
BiQAnalyzerHT52 to derive the individual methylation levels of
each Alu locus as defined by the following equation: [(# methyl-
ated CpG sites from all reads)/(# all CpG sites from all
reads)]100. Due to the nature of the HT-TREBS protocol,
these values applied to »60% of each AluYa5 element and
»85% of each AluYb8 element; the remaining portions of each
element were not part of the amplification products and thus
were not sequenced. All HT-TREBS datasets have been added
to the NCBI’s Gene Expression Omnibus53 data repository and
can be viewed under the accession number GSE74420 (http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?accDGSE74420).
COBRA (Combined Bisulfite Restriction Analysis)
Purified DNA (»500 ng) was treated with sodium bisulfite
according to the EZ DNA Methylation
TM
kit protocol (Zymo
Research). The bisulfite-treated DNA (»1 mL; »20 ng) was
then amplified by PCR using primers (Supplemental Data 3)
lacking any CpG-dinucleotides and in which all cytosines were
170 A. BAKSHI ET AL.
converted to thymines. PCR products were digested using a
restriction enzyme that recognizes at least one CpG site within
the Alu sequence and none in the flanking sequence (New Eng-
land BioLabs). The gel band densities of the restriction prod-
ucts were analyzed using the Quantity One software (BioRad)
to determine the percent methylation of the Alu elements. Data
from at least 2 restriction enzyme sites were used for all
AluYa5/Yb8 tested in this manner. All densitometric analyses
were repeated using an independent software, ImageJ, to ensure
consistency. Error bars in Fig. 2 were derived from repeating
the entire process at least 3 times, starting with bisulfite-conver-
sion and ending with the densitometry. By contrast, for the data
in Fig. 4 & Supplemental Fig. 6, the bisulfite-conversion process
could not be repeated due to insufficient DNA stocks; thus, the
error bars in Fig. 4 were derived from repeating the process
from PCR to COBRA-densitometry 2–3 times for each locus.
The boxplots in these figures were generated by combining all
the data from all the independent trials of all restriction enzyme
sites tested for the 8 normal and 40 tumor samples.
Bisulfite-NGS
One set of PCR products used for the COBRA analyses was
used for NGS-based bisulfite sequencing. This was accom-
plished as follows. Multiple PCR products of the same sample
were combined into one barcoded library, with different barco-
des for the different samples. These libraries were then end-
repaired and ligated to Ion Torrent “A” and “P1” adaptors lack-
ing 50-phosphate, using a novel scheme that uses T4 ligase and
Bst 2.0 WarmStart

DNA Polymerase (New England BioLabs).
Unligated adaptors were then removed by agarose gel extrac-
tion and further purification by Select-A-Size DNA columns
(Zymo Research), and the libraries were quantified on the Bioa-
nalyzer (Agilent Technologies). Next, each library, with its
unique barcode, was combined for multiplexed next-genera-
tion-sequencing using the Ion Torrent 318-v2 chip as described
above for HT-TREBS. After processing for quality and size
(Torrent Suite 4.4.3), reads were filtered first by barcode
sequence and then by the primer sequence for each locus from
each sample. To derive individual methylation heatmaps and
levels, the processed reads were analyzed using BiQ Analyzer54
against the unconverted sequence for each amplification prod-
uct. Percent methylation was calculated using: [(# methylated
CpG sites from all reads)/(# all CpG sites from all reads)]100.
Separate methylation levels for only the Alu locus were calcu-
lated by applying the formula above to only the CpG sites that
mapped within the Alu sequence.
Statistical analyses
COBRA-densitometry data in Fig. 2–3 were analyzed by the
Student’s t-test (P < 0.05), given that all analyzed cohorts were
normally distributed (mean D median). For HT-TREBS and
bisulfite-NGS data, at least one group in each case was not nor-
mally distributed (mean 6¼ median); thus, these data were ana-
lyzed by the non-parametric Wilcoxon-Mann-Whitney test in
RStudio. For data derived from next-generation-sequencing,
significance was set at P< 0.001 due to the high depth of cover-
age at each locus. The boxplots in Fig. 4 were also subjected to
the Wilcoxon-Mann-Whitney test; however, as these data were
derived from COBRA analyses, P < 0.05 was deemed statisti-
cally significant.
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